Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA guanine N-7 refers to the nitrogen atom at the 7th position of the guanine purine ring within the DNA structure. This specific site is the most nucleophilic position in DNA and is highly accessible within the major groove of the double helix, making it a primary target for various electrophilic chemical agents (PubChem, CID 135). In a biological context, the N7 position is involved in maintaining the structural integrity of the genetic code, though it does not participate in Watson-Crick base pairing. In oncology, this site is the principal target for alkylating agents and platinum-based chemotherapies (StatPearls, Alkylating Agents). When drugs like cyclophosphamide or cisplatin bind covalently to the N7 nitrogen, they form DNA adducts and cross-links that obstruct essential cellular processes such as DNA replication and transcription. This interference induces DNA damage responses and leads to programmed cell death (apoptosis) in rapidly proliferating cancer cells (PubMed, PMID 15769544). However, damage to this site can also be mutagenic if not properly repaired by cellular machinery, potentially leading to secondary cancers (NIH, National Cancer Institute). Therapeutic challenges include the development of resistance through enhanced DNA repair mechanisms and the non-specific nature of these drugs, which leads to significant systemic toxicity.
Covalent binding (alkylation or platination) to the N7 position of guanine bases, leading to the formation of DNA adducts, inter-strand cross-links, and intra-strand cross-links, which physically obstruct DNA replication and transcription machinery (StatPearls, Alkylating Agents; PubMed, PMID 15769544).
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA guanine N-7 (N7-G).